Our Company & Facilities
Integrated Capabilities Across the Small Molecule Lifecycle
Wilmington PharmaTech is built to support complex chemistry programs with consistency, accountability, and long-term perspective. Our organization combines experienced scientific teams, disciplined quality systems, and a US-based manufacturing platform designed to support programs from early development through commercial supply.
For more than two decades, Wilmington PharmaTech has partnered with pharmaceutical and biotechnology companies to advance challenging small molecule and HPAPI programs, providing reliable execution at every stage of the lifecycle.
Our Managing Director, Kent Payne Ph.D, describes Wilmington PharmaTech’s plans for facility expansion.
-
Facilities
Wilmington PharmaTech operates FDA-inspected facilities in Delaware on a former DuPont/Merck site with a long history of chemical manufacturing excellence.
Our campus integrates discovery and development laboratories, GMP kilo labs, pilot scale manufacturing, dedicated HPAPI suites, and analytical laboratories within a single footprint. This co-location supports efficient collaboration, rapid decision-making, and smoother transitions from development into manufacturing.
The site also includes permitted space for future expansion, enabling Wilmington PharmaTech to grow alongside client programs.
-
Leadership & Talent
Wilmington PharmaTech’s strength lies in its people.
Our teams have an average tenure of over 10 years, with many of our staff across Operations, Process Chemistry, QA, QC and Administrative working with us for as many as 20 years. Their deep institutional knowledge and technical expertise combined with hands-on management involvement ensures that your programs advance seamlessly from early development to commercial manufacture.
-
History & Evolution
Wilmington PharmaTech’s roots are tied to decades of chemical manufacturing excellence in Wilmington, Delaware.
Built on a former DuPont/Merck site, the company has evolved over more than 20 years into a trusted CDMO for complex small molecule and HPAPI programs. Continued investment, including Curewell’s strategic backing, supports ongoing growth and expanding capabilities.
SEND AN INQUIRY
We’re Ready to Start
Looking to connect? We welcome the opportunity to discuss your needs and questions.